Literature DB >> 3097151

Amplification of human B cell activation by a monoclonal antibody to the B cell-specific antigen CD22, Bp 130/140.

A Pezzutto, B Dörken, G Moldenhauer, E A Clark.   

Abstract

The B cell-specific antigen CD22 is a 130/140-Kd complex and is unique among human B cell antigens, since its surface expression is restricted to a subpopulation of Ig+ B cells. Here the function of the CD22 antigen was evaluated by using the mAb HD6, directed against one of the epitopes on the molecule. The HD6 antibody was constimulatory with anti-Ig in inducing small, dense tonsillar cells to proliferate; however, the antibody by itself was devoid of stimulatory activity. Anti-CD22 antibody also induced more anti-Ig-treated B cells to leave G0 and enter the G1 phase of the cell cycle. It also was constimulatory with low-m.w. BCGF and with an antibody to a 50-Kd polypeptide, Bp50, which mediates a BCGF-like activity. Results of kinetic experiments and analysis of different B cell fractions suggested that anti-CD22 acts during an early phase of B cell activation, probably by amplifying the anti-Ig signal. F(ab')2 fragments of anti-CD22 HD6 were as effective as the whole antibody in inducing augmentation of B cell proliferation, showing that the Fc portion of the molecule was not required for the activity. The results of these experiments, together with the intriguing distribution of the Bp 130/140 antigen in B cell ontogeny, suggest that this molecule plays an important role in the process that leads to B cell activation and proliferation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3097151

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

1.  Epitope specificity of the anti-(B cell lymphoma) monoclonal antibody, LL2.

Authors:  R Stein; E Belisle; H J Hansen; D M Goldenberg
Journal:  Cancer Immunol Immunother       Date:  1993-10       Impact factor: 6.968

Review 2.  Surface proteins and glycoproteins of human leucocytes.

Authors:  V Horejsí; V Bazil
Journal:  Biochem J       Date:  1988-07-01       Impact factor: 3.857

3.  Antigen-independent regulation of cytoplasmic calcium in B cells with a 12-kDa B-cell growth factor and anti-CD19.

Authors:  J A Ledbetter; P S Rabinovitch; C H June; C W Song; E A Clark; F M Uckun
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

4.  Functional evaluation of CD19- and CD22-negative variants of B-lymphoid cell lines.

Authors:  S Kiesel; A Pezzutto; R Haas; G Moldenhauer; B Dörken
Journal:  Immunology       Date:  1988-07       Impact factor: 7.397

5.  Variant sublines of the human B-lymphoma cells Namalwa are at different stages of differentiation.

Authors:  K Guy; P G Middleton; C M Steel
Journal:  Immunology       Date:  1987-07       Impact factor: 7.397

6.  Epstein-Barr virus latent membrane protein 2A blocks calcium mobilization in B lymphocytes.

Authors:  C L Miller; R Longnecker; E Kieff
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

7.  CD22 associates with the human surface IgM-B-cell antigen receptor complex.

Authors:  C Leprince; K E Draves; R L Geahlen; J A Ledbetter; E A Clark
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

Review 8.  CD22: an inhibitory enigma.

Authors:  Jennifer A Walker; Kenneth G C Smith
Journal:  Immunology       Date:  2007-12-07       Impact factor: 7.397

9.  Coordinated action of IgE and a B-cell-stimulatory factor on the CD23 receptor molecule up-regulates B-lymphocyte growth.

Authors:  G R Guy; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1987-09       Impact factor: 11.205

10.  Decoration of T-independent antigen with ligands for CD22 and Siglec-G can suppress immunity and induce B cell tolerance in vivo.

Authors:  Bao Hoa Duong; Hua Tian; Takayuki Ota; Gladys Completo; Shoufa Han; José Luis Vela; Miyo Ota; Michael Kubitz; Nicolai Bovin; James C Paulson; James Paulson; David Nemazee
Journal:  J Exp Med       Date:  2009-12-28       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.